Andreas Schatzlein, University College London
Andreas Schatzlein
Professor of Translational Therapeutics
University College London

Andreas has a track record in medicines development and translational research in industry and academia. A veterinary surgeon by training (BVMS, Ludwig-Maximillian Universität München), he completed is PhD research project at the Department of Medical Biophysics, Technical University of Munich, under the supervision of Prof Gregor Cevc on transdermal drug delivery using Transfersomes. The transfersomes technology was commercialised through the biotech start-up IDEA in Munich, where Andreas was intimately involved in the scientific, clinical and commercial development of its transdermal delivery nanotechnology products. In 1996 Andreas joined the Cancer Research UK Beatson Laboratories at the University of Glasgow where he became leader of the Cancer Research UK’s Experimental Therapeutics and Gene Medicines Group with a program focused on the development of advanced cancer therapeutics. As head of the centre’s Analytical Services Unit he also introduced good clinical laboratory practice (GCLP) standards into one of Europe’s largest centres for Oncology trials, facilitating pharmacokinetics and pharmacodynamics readouts in a range of Translational Clinical Trials. In 2006 AGS moved to the School of Pharmacy, London, where he was working on the development of novel cancer drugs and nanomedicines. After the School’s merger with University College London he became a full professor in 2014. Andreas has a sustained research output with over 160 publications, 15 patents/patent applications and a h-index of 40. His research is focused on the development of new medical therapies, in particular nano-enabled therapies, at the pre-clinical/clinical interface. Specifically, the research is guided by the hypothesis that the chemical engineering of biomaterials leads to supramolecular materials that could be exploited to solve a range of therapeutic challenges. The objective is to link understanding of fundamental mechanisms and processes with their biological application, and ultimately translation into medical benefit. The research has attracted over £25 million in funding from the UK Research Councils/Innovate UK, the European Union, or companies. Andreas also is co-founder and Chief Executive Officer of Nanomerics Ltd., a specialty pharmaceutical company that commercialises the technologies developed by its founders. Nanomerics has developed a pipeline of nano-enabled products and has recently out-licensed NM127, a product aimed opiate pain medications; this is now product is now being developed by the USA NIH/NCATS program and Virpax Pharmaceuticals. More recently, a 'Molecular Mask' has been developed which is able to inhibit Sars-Cov2 infections up to 10,000x. Nanomerics recently was awarded the 1st Prize in the Royal Society of Chemistry’s international Emerging Technologies Competition.